Literature DB >> 26807069

Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report.

Scott Shannon1, Janet Opila-Lehman1.   

Abstract

This case study illustrates the use of cannabidiol (CBD) oil to decrease the addictive use of marijuana and provide anxiolytic and sleep benefits. Addiction to marijuana is a chronic, relapsing disorder, which is becoming a prevalent condition in the United States. The most abundant compound in the marijuana, which is called tetrahydrocannabinol (THC), has been widely studied and known for its psychoactive properties. The second most abundant component-CBD-has been suggested to have the medicinal effects of decreasing anxiety, improving sleep, and other neuro-protective effects. The mechanism of action for CBD has been suggested to be antagonistic to the psychoactive properties of THC in many locations within the central nervous system. Such action raises the issue of whether it might be beneficial to use CBD in isolation to facilitate withdrawal of marijuana use. The specific use of CBD for marijuana reduction has not been widely studied. The patient was a 27-y-old male who presented with a long-standing diagnosis of bipolar disorder and a daily addiction to marijuana use. In the described intervention, the only change made to the patient's treatment was the addition of CBD oil with the dosage gradually decreasing from 24 to 18 mg. With use of the CBD oil, the patient reported being less anxious, as well as settling into a regular pattern of sleep. He also indicated that he had not used any marijuana since starting the CBD oil. With the decrease in the dosage to 18 mg, the patient was able to maintain his nonuse of marijuana.

Entities:  

Year:  2015        PMID: 26807069      PMCID: PMC4718203     

Source DB:  PubMed          Journal:  Integr Med (Encinitas)        ISSN: 1546-993X


  14 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

Review 2.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  The marijuana withdrawal syndrome: diagnosis and treatment.

Authors:  Margaret Haney
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

4.  Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.

Authors:  I G Karniol; I Shirakawa; N Kasinski; A Pfeferman; E A Carlini
Journal:  Eur J Pharmacol       Date:  1974-09       Impact factor: 4.432

Review 5.  Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.

Authors:  Sumner Burstein
Journal:  Bioorg Med Chem       Date:  2015-02-07       Impact factor: 3.641

6.  Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

Authors:  José Alexandre S Crippa; Guilherme Nogueira Derenusson; Thiago Borduqui Ferrari; Lauro Wichert-Ana; Fábio L S Duran; Rocio Martin-Santos; Marcus Vinícius Simões; Sagnik Bhattacharyya; Paolo Fusar-Poli; Zerrin Atakan; Alaor Santos Filho; Maria Cecília Freitas-Ferrari; Philip K McGuire; Antonio Waldo Zuardi; Geraldo F Busatto; Jaime Eduardo Cecílio Hallak
Journal:  J Psychopharmacol       Date:  2010-09-09       Impact factor: 4.153

Review 7.  Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Authors:  A W Zuardi; J A S Crippa; J E C Hallak; F A Moreira; F S Guimarães
Journal:  Braz J Med Biol Res       Date:  2006-04-03       Impact factor: 2.590

8.  Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report.

Authors:  J A S Crippa; J E C Hallak; J P Machado-de-Sousa; R H C Queiroz; M Bergamaschi; M H N Chagas; A W Zuardi
Journal:  J Clin Pharm Ther       Date:  2012-10-24       Impact factor: 2.512

9.  Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Authors:  F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe
Journal:  Transl Psychiatry       Date:  2012-03-20       Impact factor: 6.222

10.  Cannabidiol in humans-the quest for therapeutic targets.

Authors:  Simon Zhornitsky; Stéphane Potvin
Journal:  Pharmaceuticals (Basel)       Date:  2012-05-21
View more
  10 in total

Review 1.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

Review 2.  Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Authors:  G M Mandolini; M Lazzaretti; A Pigoni; L Oldani; G Delvecchio; P Brambilla
Journal:  Epidemiol Psychiatr Sci       Date:  2018-05-23       Impact factor: 6.892

3.  Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap.

Authors:  Grégoire Cleirec; Esther Desmier; Cristina Lacatus; Simon Lesgourgues; Anais Braun; Claire Peloso; Chanaëlle Obadia
Journal:  Front Psychiatry       Date:  2022-05-24       Impact factor: 5.435

4.  Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.

Authors:  Tom P Freeman; Chandni Hindocha; Gianluca Baio; Natacha D C Shaban; Emily M Thomas; Danica Astbury; Abigail M Freeman; Rachel Lees; Sam Craft; Paul D Morrison; Michael A P Bloomfield; Dominic O'Ryan; Jane Kinghorn; Celia J A Morgan; Ali Mofeez; H Valerie Curran
Journal:  Lancet Psychiatry       Date:  2020-07-28       Impact factor: 27.083

Review 5.  The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder.

Authors:  Yann Chye; Erynn Christensen; Nadia Solowij; Murat Yücel
Journal:  Front Psychiatry       Date:  2019-02-19       Impact factor: 4.157

6.  Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression.

Authors:  Clarissa Laczkovics; Oswald D Kothgassner; Anna Felnhofer; Claudia M Klier
Journal:  Neuropsychiatr       Date:  2020-02-12

Review 7.  Cannabidiol (CBD) in Cancer Management.

Authors:  Kylie O'Brien
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

Review 8.  Review: Cannabinoids as Medicinals.

Authors:  Jag H Khalsa; Gregory Bunt; Kenneth Blum; Sanjay B Maggirwar; Marc Galanter; Marc N Potenza
Journal:  Curr Addict Rep       Date:  2022-09-07

Review 9.  Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.

Authors:  Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

10.  Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma.

Authors:  Yoon Young Go; Su Ra Kim; Do Yeon Kim; Sung-Won Chae; Jae-Jun Song
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.